These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31563542)

  • 1. High yield recombinant expression and purification of oncogenic NSD1, NSD2, and NSD3 with human influenza hemagglutinin tag.
    Shen Y; Morishita M; di Luccio E
    Protein Expr Purif; 2020 Feb; 166():105506. PubMed ID: 31563542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
    Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
    Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancers and the NSD family of histone lysine methyltransferases.
    Morishita M; di Luccio E
    Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro.
    Allali-Hassani A; Kuznetsova E; Hajian T; Wu H; Dombrovski L; Li Y; Gräslund S; Arrowsmith CH; Schapira M; Vedadi M
    J Biomol Screen; 2014 Jul; 19(6):928-35. PubMed ID: 24595546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
    Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
    Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NSD family of protein methyltransferases in human cancer.
    Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
    Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
    Morishita M; di Luccio E
    Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR backbone resonance assignment and solution secondary structure determination of human NSD1 and NSD2.
    Amin N; Nietlispach D; Qamar S; Coyle J; Chiarparin E; Williams G
    Biomol NMR Assign; 2016 Oct; 10(2):315-20. PubMed ID: 27356987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
    Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
    Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
    Bennett RL; Swaroop A; Troche C; Licht JD
    Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
    He C; Li F; Zhang J; Wu J; Shi Y
    J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
    Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
    Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
    Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
    Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of NSD2 and NSD3 in overgrowth syndromes.
    Douglas J; Coleman K; Tatton-Brown K; Hughes HE; Temple IK; Cole TR; Rahman N;
    Eur J Hum Genet; 2005 Feb; 13(2):150-3. PubMed ID: 15483650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.
    Angrand PO; Apiou F; Stewart AF; Dutrillaux B; Losson R; Chambon P
    Genomics; 2001 May; 74(1):79-88. PubMed ID: 11374904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Scalable Platform for Producing Recombinant Nucleosomes with Codified Histone Methyltransferase Substrate Preferences.
    McDevitt PJ; Schneck JL; Diaz E; Hou W; Huddleston MJ; Matico RE; McCormick PM; Kirkpatrick RB
    Protein Expr Purif; 2019 Dec; 164():105455. PubMed ID: 31306746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
    Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
    Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.
    Wang GG; Cai L; Pasillas MP; Kamps MP
    Nat Cell Biol; 2007 Jul; 9(7):804-12. PubMed ID: 17589499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nizp1 is a specific NUP98-NSD1 functional interactor that regulates NUP98-NSD1-dependent oncogenic programs.
    Berardi A; Botrugno OA; Quilici G; Manteiga JMG; Bachi A; Tonon G; Musco G
    FEBS J; 2023 Apr; 290(7):1782-1797. PubMed ID: 36271682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.